Account wins from the 02/17/06 News Brief

Share this article:
PDI announced a three-year agreement with Ascend Therapeutics to promote their estrogen replacement therapy product, EstroGel, to the obstetrician/gynecologist market. PDI will initially provide a specialty sales team of 50 field representatives, with the expectation the field force will grow over time. The program is due to run through Jan. 31, 2008, with an automatic extension through Jan. 31, 2009, if certain conditions are met.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Panel votes against painkiller

Panel chair Randall Flick said QRxPharma "had not provided sufficient evidence to support a claim that Moxduo is safer than morphine or oxycodone."

Amgen sales rose by 5% in Q1

But demand for Enbrel and Aranesp slipped.

FDA reviews new painkiller

The candidate would be the first to put oxycodone and morphine in one capsule.